4D Molecular Therapeutics
FDMT
52 hedge funds and large institutions have $602M invested in 4D Molecular Therapeutics in 2020 Q4 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
55.09% more ownership
Funds ownership: 0% → 55.09% (+55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$163M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.8M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$45.7M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$43.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$42.2M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DKCM
51
Davidson Kempner Capital Management
New York
| $124K | +$124K | +3,000 | New |
|
52
Bank of America
Charlotte,
North Carolina
| $2K | +$1.65K | +40 | New |
|
FDMT Hedge Fund Activity: Q4 2020 in Review
52 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q4 2020, worth a combined $602M.
Buyers outnumbered sellers: 52 funds opened new FDMT positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $163M.
- 52 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $602M of 4D Molecular Therapeutics stock for Q4 2020.
- 52 funds opened new 4D Molecular Therapeutics positions in Q4 2020 and 0 closed out, a net change of +52 holders.
- The largest 4D Molecular Therapeutics buyer in Q4 2020 was Viking Global Investors, an estimated $163M added.
Based on aggregated 13F filings for Q4 2020.